Quantifying dose-, strain-, and tissue-specific kinetics of parainfluenza virus infection.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
08 2021
Historique:
received: 26 01 2021
accepted: 23 07 2021
revised: 24 08 2021
pubmed: 13 8 2021
medline: 23 11 2021
entrez: 12 8 2021
Statut: epublish

Résumé

Human parainfluenza viruses (HPIVs) are a leading cause of acute respiratory infection hospitalization in children, yet little is known about how dose, strain, tissue tropism, and individual heterogeneity affects the processes driving growth and clearance kinetics. Longitudinal measurements are possible by using reporter Sendai viruses, the murine counterpart of HPIV 1, that express luciferase, where the insertion location yields a wild-type (rSeV-luc(M-F*)) or attenuated (rSeV-luc(P-M)) phenotype. Bioluminescence from individual animals suggests that there is a rapid increase in expression followed by a peak, biphasic clearance, and resolution. However, these kinetics vary between individuals and with dose, strain, and whether the infection was initiated in the upper and/or lower respiratory tract. To quantify the differences, we translated the bioluminescence measurements from the nasopharynx, trachea, and lung into viral loads and used a mathematical model together a nonlinear mixed effects approach to define the mechanisms distinguishing each scenario. The results confirmed a higher rate of virus production with the rSeV-luc(M-F*) virus compared to its attenuated counterpart, and suggested that low doses result in disproportionately fewer infected cells. The analyses indicated faster infectivity and infected cell clearance rates in the lung and that higher viral doses, and concomitantly higher infected cell numbers, resulted in more rapid clearance. This parameter was also highly variable amongst individuals, which was particularly evident during infection in the lung. These critical differences provide important insight into distinct HPIV dynamics, and show how bioluminescence data can be combined with quantitative analyses to dissect host-, virus-, and dose-dependent effects.

Identifiants

pubmed: 34383757
doi: 10.1371/journal.pcbi.1009299
pii: PCOMPBIOL-D-21-00140
pmc: PMC8384156
doi:

Substances chimiques

Luciferases EC 1.13.12.-

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009299

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI139088
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Am J Epidemiol. 1975 Jun;101(6):532-51
pubmed: 168766
Clin Infect Dis. 2014 May;58(10):1357-68
pubmed: 24599766
PLoS One. 2019 Apr 15;14(4):e0214708
pubmed: 30986239
J Virol. 2018 Jan 2;92(2):
pubmed: 29093083
J Theor Biol. 2018 Nov 7;456:62-73
pubmed: 30048719
Cell Host Microbe. 2014 Nov 12;16(5):691-700
pubmed: 25456074
Mol Ther. 2010 Jun;18(6):1173-82
pubmed: 20332767
Nat Rev Immunol. 2017 Jan;17(1):7-20
pubmed: 27890913
J R Soc Interface. 2019 Nov 29;16(160):20190389
pubmed: 31771450
J Theor Biol. 2014 Apr 21;347:63-73
pubmed: 24440713
Am J Pathol. 2010 Apr;176(4):1614-8
pubmed: 20167867
J Virol. 2015 Apr;89(7):3568-83
pubmed: 25589649
Expert Rev Vaccines. 2016;15(2):189-200
pubmed: 26648515
Clin Microbiol Rev. 2003 Apr;16(2):242-64
pubmed: 12692097
PLoS Pathog. 2016 Sep 02;12(9):e1005875
pubmed: 27589232
PLoS Pathog. 2013;9(11):e1003786
pubmed: 24278024
PLoS One. 2012;7(8):e43115
pubmed: 22952637
PLoS Comput Biol. 2011 Feb;7(2):e1001081
pubmed: 21379324
Bull Math Biol. 2020 Mar 3;82(3):35
pubmed: 32125535
Front Microbiol. 2018 Jul 10;9:1554
pubmed: 30042759
J Toxicol Environ Health. 1997 Apr 11;50(5):475-506
pubmed: 9140466
J Theor Biol. 2000 Apr 7;203(3):285-301
pubmed: 10716909
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):3050-5
pubmed: 25713354
Clin Microbiol Rev. 1994 Apr;7(2):265-75
pubmed: 8055470
Clin Infect Dis. 1999 Jul;29(1):134-40
pubmed: 10433576
PLoS Pathog. 2011 Jul;7(7):e1002134
pubmed: 21750677
Sci Adv. 2020 Nov 20;6(47):
pubmed: 33097472
J Virol. 2014 Aug;88(16):9010-6
pubmed: 24899187
Elife. 2021 Jul 20;10:
pubmed: 34282728
Curr Allergy Asthma Rep. 2017 Mar;17(3):16
pubmed: 28283855
PLoS Pathog. 2021 Jul 14;17(7):e1009753
pubmed: 34260666
J Virol. 2010 Apr;84(8):3974-83
pubmed: 20130053
N Engl J Med. 2001 Jun 21;344(25):1917-28
pubmed: 11419430
Am J Rhinol. 2007 Sep-Oct;21(5):533-7
pubmed: 17999784
J Leukoc Biol. 2012 Jul;92(1):107-21
pubmed: 22504848
Immunol Rev. 2018 Sep;285(1):97-112
pubmed: 30129197
PLoS Pathog. 2016 Sep 19;12(9):e1005881
pubmed: 27644089
Science. 1996 Mar 15;271(5255):1582-6
pubmed: 8599114
Curr Opin Virol. 2012 Jun;2(3):294-9
pubmed: 22709516
Sci Rep. 2016 May 25;6:26742
pubmed: 27221530
BMC Infect Dis. 2013 Jan 23;13:28
pubmed: 23343342
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
Curr Pathobiol Rep. 2020 Sep 24;:1-13
pubmed: 32989410
J Infect Dis. 1997 Apr;175(4):807-13
pubmed: 9086134
CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):509-514
pubmed: 32558354
Virology. 2002 May 25;297(1):153-60
pubmed: 12083845
Vaccine. 2003 Jun 2;21(19-20):2362-71
pubmed: 12744867
Am J Respir Cell Mol Biol. 1992 Feb;6(2):235-43
pubmed: 1540387
Chest. 1992 Apr;101(4):1005-12
pubmed: 1555415
Adv Immunol. 1995;58:297-343
pubmed: 7741030
J Immunol. 2004 Aug 1;173(3):1978-86
pubmed: 15265932
Curr Opin Syst Biol. 2018 Dec;12:46-52
pubmed: 31723715
Vaccine. 2008 Sep 12;26 Suppl 4:D59-66
pubmed: 19230162
Virology. 2012 Nov 25;433(2):320-8
pubmed: 22959894
Nat Microbiol. 2019 Jun;4(6):914-924
pubmed: 30936491
Clin Infect Dis. 2017 Oct 16;65(9):1570-1576
pubmed: 28591775
PLoS Pathog. 2013 Mar;9(3):e1003238
pubmed: 23555251
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
J Math Biol. 2010 May;60(5):711-26
pubmed: 19633852

Auteurs

Lubna Pinky (L)

Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.

Crystal W Burke (CW)

United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, Maryland, United States of America.

Charles J Russell (CJ)

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.

Amber M Smith (AM)

Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH